Allogeneic stem cell transplantation for mantle cell lymphoma—update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74)
Rattachement africain : de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Mantle cell lymphoma (MCL) is a non-Hodgkin's lymphoma with an often aggressive course, incurable by chemotherapy. Consolidation with high-dose therapy and autologous stem cell transplantation (autoSCT) has a low transplant-related mortality but does not lead to a survival plateau. Allogeneic stem cell transplantation (alloSCT) is associated with a higher early mortality, but can cure MCL. To investigate alloSCT for therapy of MCL, we conducted two prospective trials for de novo MCL (OSHO#74) and for relapsed or refractory MCL (OSHO#60). Fifteen and 24 patients were recruited, respectively. Induction was mainly R-DHAP alternating with R-CHOP. Conditioning was either Busulfan/Cyclophosphamide or Treosulfan/Fludarabin. Either HLA-identical siblings or matched-unrelated donors with not more than one mismatch were allowed. ATG was mandatory in mismatched or unrelated transplantation. Progression-free survival (PFS) was 62% and overall survival (OS) was 68% after 16.5-year follow-up. Significant differences in PFS and OS between both trials were not observed. Patients below 56 years and patients after myeloablative conditioning had a better outcome compared to patients of the corresponding groups. Nine patients have died between day +8 and 5.9 years after SCT. Data from 7 long-term surviving patients showed an excellent Quality-of-life (QoL) after alloSCT. AlloSCT for MCL delivers excellent long-term survival data. The early mortality is higher than after autoSCT; however, the survival curves after alloSCT indicate the curative potential of this therapy. AlloSCT is a standard of care for all feasible patients with refractory or relapsed MCL and should offer to selected patients with de novo MCL and a poor risk profile. For defining the position of alloSCT in the therapeutic algorithm of MCL therapy, a randomized comparison of autoSCT and alloSCT is mandatory.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Allogeneic stem cell transplantation for mantle cell lymphoma—update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74)
- Date Crossref
- 08/04/2021
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Universitätsmedizin Greifswald pays non établi dans la noticeÉtablissement de santé
-
Universität Greifswald pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Leipzig Department Haematology/Oncology pays non établi dans la noticeÉtablissement de santé
-
Jena University Hospital pays non établi dans la noticeÉtablissement de santé
-
Martin Luther University Halle-Wittenberg Department Haematology/Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Otto-von-Guericke-Universität Magdeburg pays non établi dans la noticeUniversité ou école supérieure
-
Dietrich Bonhoeffer Klinikum pays non établi dans la noticeÉtablissement de santé
-
Klinikum Ernst von Bergmann pays non établi dans la noticeÉtablissement de santé
-
Palliative Care - University of Greifswald Department of Internal Medicine C - Haematology and Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Palliative Care – University of Greifswald Department of Internal Medicine C – Haematology and Oncology pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Jena Department for Haematology and Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Otto von Guericke University Department Haematology/Oncology pays non établi dans la noticeUniversité ou école supérieure
Universitätsmedizin Greifswald, Universität Greifswald et Department Haematology/Oncology — University Hospital Leipzig, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.